1800 244 735

HD Therapeutics Conference 2012 Updates: Day 2

Our second daily report from the annual Huntington’s Disease Therapeutics Conference in Palm Springs, California. The second day’s sessions focused on gene silencing. You can tweet @HDBuzzFeed or email [email protected] with your questions, comments and queries.

Wednesday, February 29, 2012

9:03 – HD Therapeutics Conference Update: This morning is focused on gene silencing – a very exciting potential therapy. Stand by!

9:35 – Beverly Davidson (University of Iowa): silencing the mutant HD gene in mice has clear benefits, but we need to consider any unintended toxic effects

9:45 – Davidson is behind one of three recent papers showing huntingtin gene silencing safe in primates – a key step to human trials

9:49 – Davidson’s team is now working on new gene silencing drugs that silence the mutant copy of the gene more than the ‘healthy’ copy.

9:50 – Targeting the mutant gene selectively might be safer but is more challenging. Both approaches are being worked on.

10:06 – Frank Bennett (Isis Pharmaceuticals) uses slightly different DNA-like molecules called ASOs to silence the Huntingtin gene

10:07 – Bennett: Huntingtin seems to be relatively easy to silence compared to other genes – lucky break!

10:00 – Bennett’s ASO drugs are absorbed into cells better then RNAi drugs. Might make it easier to get to patients – no brain surgery?

10:13 – Bennett’s company Isis pharmaceuticals is experienced in gene silencing – 2,000+ patients with other diseases have received their drugs

10:17 – Bennett: when tested in 2 different HD mouse models, ASO gene silencing drugs produced improvements in coordination and cognition

10:19 – Bennett: infusion of ASO into the fluid at the base of the spine in primates is enough to get the drug to large areas of the brain

10:22 – Bennett: even one-off injections of the gene silencing ASO may be enough to treat the brain. But deep brain regions harder to reach

10:25 – Bennett: many people have small spelling differences, apart from the expanded CAG, between the 2 copies of Huntingtin gene. These differences can be targeted, to design drugs that silence only the mutant gene.

11:04 – Steve Zhang (Sangamo BioSciences): ‘zinc finger proteins’ can bind to specific DNA sequences, raising the possibility of ‘editing’ our genes

11:07 – For anyone wanting more detail, video of the talks will be available online soon, and we’re writing a summary article too

11:00 – Zhang: other uses of zinc finger proteins include designing stem cells to study generic diseases in human cells

11:18 – Zhang’s company Sangamo has successfully treated hemophilia in a mouse model using ‘genome editing’

11:19 – Zhang: Zinc fingers can also be used to switch genes on and off, another possible approach to gene silencing

11:20 – Zhang: we could also try to switch on helpful genes, so that the brain produces more protective chemicals

11:25 – Zhang: zinc finger drug that makes the brain produce the protective chemical GDNF is about to start a trial in Parkinson’s disease

11:26 – Sangamo is now involved in Huntington’s disease research.

11:29 – Zhang: Sangamo’s current strategy is to try to reduce Huntingtin production with a tailor-made zinc finger drug

11:36 – Zhang: they’re also working on a zinc finger silencing drug that only works on huntingtin genes with expanded CAG repeats

11:53 – Bill Kaemmerer (Medtronic): To make new silencing trials happen we need ‘biomarkers’- tests of safety & measurements to tell us if it’s working

12:02 – Kaemmerer: A combination of MR imaging, CSF chemicals and clinical measures will be used for early RNAi gene silencing trials

12:07 – Kaemmerer is part of the team behind another recent primate safety trial of huntingtin gene silencing

12:37 – Neil Aronin (University of Massachusetts School of Medicine) and his team are trying to understand how one gene silencing approach, RNAi, works in great detail to design good drugs

12:46 – Aronin and his team are are using sheep to practice the neurosurgical techniques needed for gene silencing trials in humans

Sunset conclusions

Several different strategies are being developed in parallel to ‘silence’ the huntingtin gene that’s the ultimate cause of all problems in HD. There are a few wrinkles to iron out, but basically so far each approach has cleared every hurdle it’s encountered. Several clinical trials involving HD patients are being planned, all aiming for a rapid start – within months rather than years. The stakes are high, but it’s a genuinely exciting time.

Latest Research Articles

Cry your eyes out: detecting huntingtin in tears

Published date: 10 April, 2024

A recently published collaboration between academic researchers and pharmaceutical companies was successful at detecting huntingtin in tears. The scientists were looking for a new, easy way to track Huntington’s disease (HD). If you don’t mind shedding a tear or two, they found it! Biomarkers – biological metrics in tune with disease progression Tracking disease progression ... Read more

The director’s cut: how CAG repeats change the editing of genetic messages

Published date: 26 March, 2024

Long repetitive sequences of C-A-G letters in the DNA code are associated with at least 12 genetic diseases, including Huntington’s disease (HD). A group of scientists in Massachusetts, USA, have recently developed a new genetic strategy to study how CAG repeats can lead to harmful proteins being made in cells, causing cells to become unhealthy. ... Read more

Understanding expansions at the single cell level

Published date: 12 March, 2024

In two recent studies, researchers looked at how different parts of the brain are affected by CAG expansions in Huntington’s disease (HD) at the level of individual brain cells. The scientists looked at post-mortem brains from people with and without HD to track molecular changes in different brain regions called the cortex and striatum. These ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 3

Published date: 7 March, 2024

HDBuzz is back for the last day of the CHDI HD Therapeutics Conference: Thursday February 29th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. From genes to medicines The morning session will focus on how human genetics is driving the development of therapeutics. “Genetic modifiers” are genes ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 2

Published date: 6 March, 2024

HDBuzz is back for Day 2 of the CHDI HD Therapeutics Conference: Wednesday February 28th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. It’s a brain disease This morning’s session is titled “It’s a brain disease” and will feature talks about BRAINSSSS! HD scientists are a bit ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 1

Published date: 5 March, 2024

The HDBuzz team recently convened in Palm Springs, California, along with hundreds of other scientists from all over the globe, for the 19th Annual HD Therapeutics Conference, hosted by the HD research foundation CHDI. From Tuesday February 27th through Thursday February 29th, we live-tweeted dozens of scientific talks by world experts in Huntington’s disease research, ... Read more